Bernd Hentsch
Directeur/Bestuurslid bij G2M Cancer Drugs AG
Oorsprong van het eerstegraads netwerk van Bernd Hentsch
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Bernd Hentsch via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Biotechnology | Chief Executive Officer | |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Medical Specialties | Chief Executive Officer | |
Satosea Oncology GmbH | Chief Executive Officer | ||
Thermosome GmbH
Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Pharmaceuticals: Major | Chairman | |
Technische Universität Braunschweig | College/University | Corporate Officer/Principal | |
Heartbeat.bio AG
Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Eberhard Karls Universität Tübingen | College/University | Undergraduate Degree | |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Biotechnology | Chairman | |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Igeneon AG | Chief Executive Officer | ||
Max Planck Institute For Biophysical Chemistry | College/University | Doctorate Degree | |
Aphton Corp.
Aphton Corp. BiotechnologyHealth Technology Aphton Corp. operates as a biopharmaceutical company, which is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The company was founded on May 12, 1981 and is headquartered in Philadelphia, PA. | Biotechnology | Chief Operating Officer | |
Kiadis Pharma Deutschland GmbH
Kiadis Pharma Deutschland GmbH Pharmaceuticals: MajorHealth Technology Kiadis Pharma Deutschland GmbH develops drugs for blood cancer. The private company is based in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Kiadis Pharma Canada, Inc.
Kiadis Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kiadis Pharma Canada, Inc. manufactures and supplies pharmaceutical products. The company is based in Saint-Laurent, Canada. | Pharmaceuticals: Major | Chief Executive Officer | |
Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
LSP Services Deutschland GmbH | Investment Managers | Private Equity Investor | |
4SC AG | Biotechnology | Director/Board Member | |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistieken
Internationaal
Duitsland | 15 |
Oostenrijk | 4 |
Nederland | 3 |
Verenigde Staten | 2 |
Canada | 2 |
Sectoraal
Health Technology | 13 |
Consumer Services | 4 |
Commercial Services | 3 |
Finance | 2 |
Health Services | 2 |
Operationeel
Chief Executive Officer | 12 |
Director/Board Member | 3 |
Chairman | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sterkste connecties
Insiders | |
---|---|
Manfred Rüdiger | 22 |
- Beurs
- Insiders
- Bernd Hentsch
- Bedrijfsconnecties